尖峯集團(600668.SH):尖峯藥業的鹽酸奧洛他定滴眼液擬中標第四批全國藥品集採
格隆匯 2 月 4日丨尖峯集團(600668.SH)公佈,2021年2月3日,公司控股子公司浙江尖峯藥業有限公司(“尖峯藥業”)參加了國家組織藥品集中採購和使用聯合採購辦公室(“聯合採購辦公室”)組織的第四批全國藥品集中採購的投標,尖峯藥業的鹽酸奧洛他定滴眼液擬中標此次集中採購。
尖峯藥業此次擬中標的產品鹽酸奧洛他定滴眼液於2019年4月取得國家藥品監督管理局核准並簽發《藥品註冊批件》,此前市場銷售量較小,該產品2019年度以及2020年1-9月銷售收入分別為5.65萬元和97.74萬元,分別佔公司2019年度營業收入約35.48億元的0.0016%和2020年1-9月營業收入約22.41億元的0.04%。
此次集中採購是國家組織的第四批藥品集中帶量採購,採購週期中,醫療機構將優先使用此次藥品集中採購中選藥品,並確保完成約定採購量。此次擬中選產品價格與原價相比有一定程度下降。若公司後續簽訂採購合同並實施後,將有利於擴大該產品的銷售規模,提高市場佔有率,提升公司品牌影響力,具有積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.